Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555)
Clinical trial NCT03665597 · COMPLETED
Trial details
- NCT number
- NCT03665597
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-11-19
- Primary completion
- 2023-12-04
- Enrollment
- 138
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.